Sean Z Zhao
Overview
Explore the profile of Sean Z Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolfe F, Michaud K, Zhao S
J Clin Rheumatol
. 2006 Oct;
9(6):344-53.
PMID: 17043442
Nonsteroidal anti-inflammatory medications (NSAIDs) may be accompanied by clinically important renal side effects. We compared the rate of reported side effects from celecoxib, rofecoxib, and nonspecific (NS) NSAIDs and their...
2.
Zhao S, Chung F, Hanna D, Raymundo A, Cheung R, Chen C
J Pain Symptom Manage
. 2004 Jun;
28(1):35-46.
PMID: 15223083
This health outcomes analysis based on data from a randomized, double-blind, placebo-controlled trial determined dose-response relationship between opioid use and related symptoms. All patients received intravenous fentanyl on demand for...
3.
Zhao S, Wentworth C, Burke T, Makuch R
Pharmacoepidemiol Drug Saf
. 2004 May;
13(5):277-87.
PMID: 15133778
Purpose: To compare RA and OA patients' time-to-switch after newly initiating treatment with three most commonly used non-specific (NS)-NSAIDs and two COX-2 inhibitors, celecoxib and rofecoxib. Methods: Managed care enrollees...
4.
Wolfe F, Michaud K, Burke T, Zhao S
J Rheumatol
. 2004 Feb;
31(2):355-8.
PMID: 14760808
Objective: To compare COX-2-specific inhibitor therapy with conventional nonspecific nonsteroidal antiinflammatory drugs (NS NSAID), and investigate the effect of demographic and disease factors on NSAID duration of use. Methods: A...
5.
Goldstein J, Zhao S, Burke T, Palmer R, Allmen H, Henderson S
Am J Gastroenterol
. 2003 Dec;
98(12):2627-34.
PMID: 14687808
Objective: The aim of this study was to compare the risk of outpatient medical claims for UGI symptoms among new users of celecoxib versus ibuprofen, and naproxen. Methods: The study...
6.
Zhao S, Burke T, Whelton A, Allmen H, Henderson S
Am J Manag Care
. 2002 Nov;
8(15 Suppl):S414-27.
PMID: 12416791
Objective: To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice. Methods: Stable hypertensive patients without a history...
7.
Zhao S, Burke T, Whelton A, Allmen H, Henderson S
Am J Manag Care
. 2002 Nov;
8(15 Suppl):S401-13.
PMID: 12416790
Objective: To determine the incremental cost of blood pressure (BP) destabilization among patients with stable hypertension who newly initiate therapy with celecoxib, rofecoxib, or 3 commonly used nonspecific nonsteroidal anti-inflammatory...
8.
Zhao S, Burke T, Whelton A, Allmen H, Henderson S
Am J Manag Care
. 2002 Nov;
8(15 Suppl):S392-400.
PMID: 12416789
Objective: To evaluate the baseline cardiovascular (CV) risk of hypertensive patients newly starting cyclooxygenase (COX)-2-specific inhibitors (celecoxib or rofecoxib) or nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: Cross-sectional analysis was performed...
9.
Huerta C, Zhao S, Rodriguez L
Pharmacotherapy
. 2002 Sep;
22(9):1091-6.
PMID: 12222543
Study Objectives: To estimate the incidence of acute liver injury in patients with diabetes and compare it with the corresponding incidence in the general population, and to examine the association...
10.
Zhao S, Dodge W, Spalding W, Barr C, Li J
Clin Ther
. 2002 Jun;
24(5):818-34.
PMID: 12075949
Background: Staphylococcus (Staph) and Streptococcus (Strep) infections are important causes of morbidity and mortality worldwide. The economic burden of these infections is also significant, especially among hospitalized patients. Objective: The...